drugset / Trial / NCT03472014

Special Access Program IMVAMUNE®

NCT03472014

Phase 4 Completed 22 enrolled Bavarian Nordic
NaSingle-groupOpen-labelPrevention

Summary

Prophylactic smallpox vaccination for personnel actively working with or in the vicinity of replicating vaccinia virus

Timeline

Start
2010-04-22
Primary completion
2014-11-14
Completion
2014-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject IMVAMUNE Vaccine 0.5 ml Subcutaneous

Indications

No indication recorded.